Mira Pharmaceuticals, Inc. has announced positive results from preclinical studies for SKNY-1, an oral drug candidate targeting obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, reproducible systemic exposure, and robust brain and liver penetration following oral administration. Peak plasma concentrations suggest the potential for a convenient once-daily oral dosing regimen. These findings complement previous efficacy and behavioral studies showing significant body weight reduction, lean body mass preservation, improved metabolic parameters, and reduced compulsive feeding and nicotine-seeking behaviors. SKNY-1's differentiated pharmacological profile, including biased CB1 receptor modulation and selective MAO-B inhibition, is highlighted as a key advantage over earlier CB1-targeting therapies that faced neuropsychiatric side effects.